Stock of the Day

August 28, 2023

Insulet (PODD)

$148.66
+$3.53 (+2.4%)
Market Cap: $10.07B

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Today's Trend

Insulet Corporation (NASDAQ: PODD) is facing increased legal-risk scrutiny, as several law firms publicized a pending securities class-action lawsuit and the deadline for investors to seek lead-plaintiff status. The legal headlines create a potential overhang for the shares, although the stock has increased as investors continue to weigh the company’s operating performance against the litigation concerns.

  • Insulet’s most recent quarterly results provide a favorable fundamental backdrop: revenue rose 23.5% year over year to $801.7 million and adjusted earnings of $1.66 per share exceeded consensus expectations of $1.47. This strength may be helping offset concerns related to the lawsuit.
  • Multiple investor-rights firms—including Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and others—are soliciting affected shareholders ahead of the August 31, 2026 lead-plaintiff deadline. The announcements largely repeat the same litigation information rather than representing separate lawsuits or new company disclosures. Faruqi securities class-action deadline notice
  • The filed class action alleges that Insulet and certain officers violated federal securities laws by making misleading statements or failing to disclose material information. One notice specifically points to alleged manufacturing problems at the company’s Acton facility, including medical-device corrections affecting millions of Pods, despite SEC filings that described quality-assurance inspections during manufacturing. The allegations have not been proven, but potential damages, legal costs, reputational harm, and further regulatory or operational consequences could pressure valuation. Bronstein class-action announcement Levi and Korsinsky lawsuit notice
← Previous Stock of the DayNext Stock of the Day →

Recent News